Although intratumor heterogeneity may interfere with prediction of the patient's tumor genetic profile, our data suggest that analyses of proof reading POLE mutations and MSI by mononucleotide markers will be useful as biomarkers for identifying patients who have a good prognosis and may not require intensive postoperative radiotherapy or even chemotherapy. Here, POLE is linked to neoplasm.